The spike protein of SARS-CoV-2 virus is an attractive candidate, as it is the portion of the virus that is exposed to the environment and engages the ACE2 receptor for viral entry into the cell, so if antibodies can be raised to block its function, we would have an effective vaccine. Until efficacy can be demonstrated in the vaccine trials, the exact form of the immunogen that can lead to the production of nAbs is largely unknown. The vaccine has to deliver immunogens (usually viral proteins but can be the genetic material of the immunogens as DNA or RNA) to activate the adaptive immune response to produce antibodies. There are a number of ongoing vaccine trials, and their goals are to raise neutralizing antibodies (nAbs) in people who receive the vaccine. To ultimately stop the spread of the virus, we need an effective vaccine. Stanford-Coulter Translational Research Grants Program.Cryo-electron tomography of coronavirus infected cells.Cryo-EM of molecular components of COVID-19.New class of antivirals in testing against SARS-CoV-2 virus.Computational screens identify possible drug candidates to treat Covid-19.Potential T-cell and B-cell Epitopes of 2019-nCoV.Rational design of a new class of protease inhibitors.Leveraging spectrally encoded beads for highly multiplexed profiling of SARS-CoV-2.COVID-19 diagnostic standards development partnership.A multiplex ELISA based diagnostics for COVID19.Serologic testing for SARS-CoV-2 immunity.New genetic method of using CRISPR to eliminate COVID-19 virus genomes in cells.1000x1000: A cotton-candy (Rotary jet spinning) machine for distributed manufacturing of N95 mask filter material.Particle Filtration Efficiency Test Protocol.
Pneumask: Reusable Full-Face Snorkel Mask PPE Project.Pufferfish: Open-Source Full-Featured Ventilator.
0 kommentar(er)
